Skip to content

Annexon ANNX PP&E (Net)

PP&E (Net) at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$274K+43.5%
Omeros logo
OmerosOMER
$1.53M-36.8%
Vor Biopharma logo
Vor BiopharmaVOR
$565K-90.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$342K-43.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.28M-26.5%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$212K-74.0%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's PP&E (net)?
Annexon (ANNX) reported PP&E (net) of $10.11M in Q1 2026.
How has Annexon's PP&E (net) changed year-over-year?
Annexon's PP&E (net) decreased by 17.1% year-over-year, from $12.19M to $10.11M.
What is the long-term trend for Annexon's PP&E (net)?
Over 5 years (2020 to 2025), Annexon's PP&E (net) has grown at a 40.6% compound annual growth rate (CAGR), from $1.94M to $10.62M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.